PolyPid Posts Q3 Loss of $0.24/Share; Cash to Fund Operations Into 2028 Ahead of Nov 28 PDUFA
PYPD sits 99% above its 52-week low of $3.5 on elevated volume (3.5× avg).
Summary
PolyPid reported a Q3 2026 net loss of $5.8 million ($0.24 per share) and said its $15.5 million cash balance plus a post-quarter $15 million Azurity milestone funds operations into 2028, three weeks before the November 28 D-PLEX100 PDUFA date.
Key Events · Earnings and Guidance · PYPD
-
Q3 Loss Narrows to $0.24/Share
Net loss of $5.8 million, or $(0.24) per share, versus $(0.37) in Q3 2025; the nine-month loss was $21.3 million, or $(0.94) per share.
-
Cash Runway Extended Into 2028
Cash, cash equivalents and short-term deposits of $15.5 million at September 30, 2026, plus a $15 million Azurity milestone received after quarter end; management says this funds operations into 2028.
-
Azurity Deal Delivers $30M So Far
$15 million on signing in July 2026 plus $15 million on FDA NDA acceptance, with over $290 million in remaining regulatory, launch and sales milestones plus mid-teen to mid-twenties royalties.
-
PDUFA Decision Due November 28, 2026
D-PLEX100 NDA is under FDA Priority Review with a November 28, 2026 goal date; labeling talks are underway and a U.S. launch by Azurity is targeted for early 2027.
Analysis · PYPD · Industrial Applications And Services
With the November 28, 2026 PDUFA goal date for D-PLEX100 just three weeks away, the runway this quarter buys matters more than the loss itself. Cash and short-term deposits stood at $15.5 million on September 30, and a $15 million Azurity milestone landed after the quarter closed; management now says that plus expected partner proceeds funds operations into 2028, clearing any near-term financing overhang as the binary FDA decision approaches. The quarter produced a $5.8 million net loss, or $0.24 per share, versus $0.37 a year ago, aided by $2.5 million of other income from recognizing deferred revenue after the ADVANZ termination. Per-share figures also rest on a larger base, with the share count up to 21.1 million from 18.2 million at year-end 2025.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYPD was trading at $6.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.1M. The 52-week trading range was $3.50 to $7.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.